The impact of JAK inhibitor treatment on anxiety and depression outcomes and the role of eyebrow and eyelash hair regrowth in alopecia areata: TARGET-DERM.

Challenge

The impact of JAK inhibitor treatment on psychiatric comorbidities—specifically anxiety and depression—and the role of eyebrow and eyelash regrowth on patient-reported outcomes in AA had not been characterized in a real-world longitudinal US/Canadian cohort, limiting understanding of the full patient benefit profile of JAK inhibitor therapy.

Solution

The TARGET-DERM AA registry was analyzed to assess longitudinal changes in PROMIS anxiety and depression scores and the correlation between eyebrow/eyelash regrowth and patient-reported outcomes among patients receiving JAK inhibitor treatment.

Impact

Demonstrating that JAK inhibitor treatment improves psychiatric outcomes and that eyebrow/eyelash regrowth meaningfully affects patient experience provides real-world evidence of the holistic benefit of JAK inhibitors in AA, supporting label claims and payer value arguments beyond scalp hair regrowth alone.